AAPL297.04+0.03 (+0.01%) ▲|ABBV233.60+3.59 (+1.56%) ▲|ABT90.22+2.39 (+2.72%) ▲|ACN126.88+2.05 (+1.64%) ▲|ADBE197.77+2.87 (+1.47%) ▲|AMAT580.99-59.19 (-9.25%) ▼|AMD517.30-34.33 (-6.22%) ▼|AMGN347.52+2.80 (+0.81%) ▲|AMT178.51+2.08 (+1.18%) ▲|AMZN234.74+1.95 (+0.84%) ▲|AVGO380.92-11.22 (-2.86%) ▼|AXP337.37-0.71 (-0.21%) ▼|BA218.33-2.50 (-1.13%) ▼|BAC57.89+0.52 (+0.90%) ▲|BKNG168.67+0.90 (+0.53%) ▲|BLK1,016.29-35.45 (-3.37%) ▼|BMY55.85+1.15 (+2.10%) ▲|BNY147.50+1.06 (+0.72%) ▲|BRK-B492.96+4.27 (+0.87%) ▲|C145.34-0.34 (-0.23%) ▼|CAT985.22-37.06 (-3.63%) ▼|CL91.42+2.75 (+3.10%) ▲|CMCSA23.01+0.69 (+3.09%) ▲|COF197.35-3.35 (-1.67%) ▼|COP109.70+0.00 (+0.00%) ▲|COST958.86+7.51 (+0.79%) ▲|CRM153.84+3.72 (+2.48%) ▲|CSCO121.00-0.53 (-0.44%) ▼|CVS101.40+0.10 (+0.10%) ▲|CVX175.77+0.71 (+0.40%) ▲|DE591.40-7.20 (-1.20%) ▼|DHR178.80+0.61 (+0.34%) ▲|DIS103.66+1.21 (+1.18%) ▲|DUK125.25+1.73 (+1.40%) ▲|EMR143.58-6.63 (-4.41%) ▼|FDX321.20-7.59 (-2.31%) ▼|GD349.01+5.65 (+1.64%) ▲|GE355.79+0.67 (+0.19%) ▲|GEV1,039.82-87.78 (-7.78%) ▼|GILD125.63+0.76 (+0.61%) ▲|GM79.20-1.23 (-1.53%) ▼|GOOG346.27-2.51 (-0.72%) ▼|GOOGL346.86-2.70 (-0.77%) ▼|GS1,098.32-8.06 (-0.73%) ▼|HD325.59-1.03 (-0.32%) ▼|HON221.91-6.20 (-2.72%) ▼|IBM263.24+11.02 (+4.37%) ▲|INTC132.52-8.42 (-5.97%) ▼|INTU258.39+0.62 (+0.24%) ▲|ISRG402.25-0.70 (-0.17%) ▼|JNJ238.44+7.15 (+3.09%) ▲|JPM334.36+2.88 (+0.87%) ▲|KO80.19+0.66 (+0.83%) ▲|LIN514.63-2.08 (-0.40%) ▼|LLY1,107.53+5.45 (+0.49%) ▲|LMT501.23+7.63 (+1.55%) ▲|LOW214.15-0.25 (-0.12%) ▼|LRCX370.23-39.31 (-9.60%) ▼|MA488.29+4.20 (+0.87%) ▲|MCD271.95+1.85 (+0.68%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.48+1.21 (+1.53%) ▲|META563.77-0.08 (-0.01%) ▼|MMM162.01-1.22 (-0.74%) ▼|MO71.42+1.91 (+2.75%) ▲|MRK119.16+3.68 (+3.18%) ▲|MS226.52-0.58 (-0.25%) ▼|MSFT373.41+6.07 (+1.65%) ▲|MU1,049.14-162.24 (-13.39%) ▼|NEE86.46+0.38 (+0.44%) ▲|NFLX73.06+0.18 (+0.25%) ▲|NKE42.71-0.49 (-1.12%) ▼|NOW96.45+3.44 (+3.70%) ▲|NVDA200.95-7.70 (-3.69%) ▼|ORCL166.06-9.01 (-5.15%) ▼|PEP142.02+1.31 (+0.93%) ▲|PFE24.90-0.19 (-0.74%) ▼|PG150.97+3.29 (+2.23%) ▲|PLTR116.97-2.53 (-2.12%) ▼|PM177.44+4.27 (+2.47%) ▲|QCOM203.28-18.63 (-8.39%) ▼|RTX185.40+3.57 (+1.96%) ▲|SBUX101.08+0.93 (+0.93%) ▲|SCHW92.85+0.82 (+0.89%) ▲|SO94.82+1.39 (+1.49%) ▲|SPG216.79+2.22 (+1.03%) ▲|T22.92+0.82 (+3.69%) ▲|TMO467.35+3.34 (+0.72%) ▲|TMUS184.49+4.43 (+2.46%) ▲|TSLA381.24-23.81 (-5.88%) ▼|TXN302.71-29.58 (-8.90%) ▼|UBER69.70-1.73 (-2.42%) ▼|UNH408.04+1.36 (+0.33%) ▲|UNP259.48-0.43 (-0.17%) ▼|UPS105.98-1.27 (-1.18%) ▼|USB59.94+1.26 (+2.15%) ▲|V328.67+2.07 (+0.63%) ▲|VZ46.77+1.41 (+3.10%) ▲|WFC84.09+0.25 (+0.29%) ▲|WMT119.54+2.36 (+2.01%) ▲|XOM139.93+1.46 (+1.05%) ▲|AAPL297.04+0.03 (+0.01%) ▲|ABBV233.60+3.59 (+1.56%) ▲|ABT90.22+2.39 (+2.72%) ▲|ACN126.88+2.05 (+1.64%) ▲|ADBE197.77+2.87 (+1.47%) ▲|AMAT580.99-59.19 (-9.25%) ▼|AMD517.30-34.33 (-6.22%) ▼|AMGN347.52+2.80 (+0.81%) ▲|AMT178.51+2.08 (+1.18%) ▲|AMZN234.74+1.95 (+0.84%) ▲|AVGO380.92-11.22 (-2.86%) ▼|AXP337.37-0.71 (-0.21%) ▼|BA218.33-2.50 (-1.13%) ▼|BAC57.89+0.52 (+0.90%) ▲|BKNG168.67+0.90 (+0.53%) ▲|BLK1,016.29-35.45 (-3.37%) ▼|BMY55.85+1.15 (+2.10%) ▲|BNY147.50+1.06 (+0.72%) ▲|BRK-B492.96+4.27 (+0.87%) ▲|C145.34-0.34 (-0.23%) ▼|CAT985.22-37.06 (-3.63%) ▼|CL91.42+2.75 (+3.10%) ▲|CMCSA23.01+0.69 (+3.09%) ▲|COF197.35-3.35 (-1.67%) ▼|COP109.70+0.00 (+0.00%) ▲|COST958.86+7.51 (+0.79%) ▲|CRM153.84+3.72 (+2.48%) ▲|CSCO121.00-0.53 (-0.44%) ▼|CVS101.40+0.10 (+0.10%) ▲|CVX175.77+0.71 (+0.40%) ▲|DE591.40-7.20 (-1.20%) ▼|DHR178.80+0.61 (+0.34%) ▲|DIS103.66+1.21 (+1.18%) ▲|DUK125.25+1.73 (+1.40%) ▲|EMR143.58-6.63 (-4.41%) ▼|FDX321.20-7.59 (-2.31%) ▼|GD349.01+5.65 (+1.64%) ▲|GE355.79+0.67 (+0.19%) ▲|GEV1,039.82-87.78 (-7.78%) ▼|GILD125.63+0.76 (+0.61%) ▲|GM79.20-1.23 (-1.53%) ▼|GOOG346.27-2.51 (-0.72%) ▼|GOOGL346.86-2.70 (-0.77%) ▼|GS1,098.32-8.06 (-0.73%) ▼|HD325.59-1.03 (-0.32%) ▼|HON221.91-6.20 (-2.72%) ▼|IBM263.24+11.02 (+4.37%) ▲|INTC132.52-8.42 (-5.97%) ▼|INTU258.39+0.62 (+0.24%) ▲|ISRG402.25-0.70 (-0.17%) ▼|JNJ238.44+7.15 (+3.09%) ▲|JPM334.36+2.88 (+0.87%) ▲|KO80.19+0.66 (+0.83%) ▲|LIN514.63-2.08 (-0.40%) ▼|LLY1,107.53+5.45 (+0.49%) ▲|LMT501.23+7.63 (+1.55%) ▲|LOW214.15-0.25 (-0.12%) ▼|LRCX370.23-39.31 (-9.60%) ▼|MA488.29+4.20 (+0.87%) ▲|MCD271.95+1.85 (+0.68%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.48+1.21 (+1.53%) ▲|META563.77-0.08 (-0.01%) ▼|MMM162.01-1.22 (-0.74%) ▼|MO71.42+1.91 (+2.75%) ▲|MRK119.16+3.68 (+3.18%) ▲|MS226.52-0.58 (-0.25%) ▼|MSFT373.41+6.07 (+1.65%) ▲|MU1,049.14-162.24 (-13.39%) ▼|NEE86.46+0.38 (+0.44%) ▲|NFLX73.06+0.18 (+0.25%) ▲|NKE42.71-0.49 (-1.12%) ▼|NOW96.45+3.44 (+3.70%) ▲|NVDA200.95-7.70 (-3.69%) ▼|ORCL166.06-9.01 (-5.15%) ▼|PEP142.02+1.31 (+0.93%) ▲|PFE24.90-0.19 (-0.74%) ▼|PG150.97+3.29 (+2.23%) ▲|PLTR116.97-2.53 (-2.12%) ▼|PM177.44+4.27 (+2.47%) ▲|QCOM203.28-18.63 (-8.39%) ▼|RTX185.40+3.57 (+1.96%) ▲|SBUX101.08+0.93 (+0.93%) ▲|SCHW92.85+0.82 (+0.89%) ▲|SO94.82+1.39 (+1.49%) ▲|SPG216.79+2.22 (+1.03%) ▲|T22.92+0.82 (+3.69%) ▲|TMO467.35+3.34 (+0.72%) ▲|TMUS184.49+4.43 (+2.46%) ▲|TSLA381.24-23.81 (-5.88%) ▼|TXN302.71-29.58 (-8.90%) ▼|UBER69.70-1.73 (-2.42%) ▼|UNH408.04+1.36 (+0.33%) ▲|UNP259.48-0.43 (-0.17%) ▼|UPS105.98-1.27 (-1.18%) ▼|USB59.94+1.26 (+2.15%) ▲|V328.67+2.07 (+0.63%) ▲|VZ46.77+1.41 (+3.10%) ▲|WFC84.09+0.25 (+0.29%) ▲|WMT119.54+2.36 (+2.01%) ▲|XOM139.93+1.46 (+1.05%) ▲|
20.6 C
New York
Tuesday, June 23, 2026

Tag: medicine

newssourceFORcompanyinformationcontent1marketreleases

PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications

Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations 
Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations

Johnson & Johnson showcases latest advancements in Alzheimer’s research at AAIC 2025

Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection New findings highlight the central role of...

Exhale Expands THCA Collection With Two Best THCA Flower Strains: Godfather OG and Hawaiian Haze

Exhale Wellness, a leading hemp-based wellness brands, introduced two new THCA flower strains in July 2025. Read more about their features. 
Exhale Wellness, a leading hemp-based wellness brands, introduced two new THCA flower strains in July 2025. Read more about their features.

Citryll Announces Formation of Scientific Advisory Board

CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD

Happy Docs Make Happy Patients

AI technology boosts face-to-face time with patients, earns Mercy national recognition for physician satisfaction ST. LOUIS, July 23, 2025 /PRNewswire/ -- Mercy's strategic and carefully planned...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

DEADLINE ALERT for VSTS, RCKT, TEM, and DDD: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

The Power of Massage Therapy for Autoimmune Diseases: AMTA Highlights Emerging Research

EVANSTON, Ill., July 23, 2025 /PRNewswire/ -- The American Massage Therapy Association (AMTA) is committed to advancing integrative health care by spotlighting the powerful role...

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.

Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons

BEACHWOOD, Ohio, July 23, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells...

Ipsen announces changes to its Executive Committee

PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers